2025 · 1st Quarter (Jan 1 - Mar 31)
Filed by CROSSROADS STRATEGIES, LLC.
Open official filingSource-reported fields
Literal source text
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2026 National Defense Authorization Act; PBM reform; S.891, Bipartisan Health Care Act.
Literal federal measure citations: S.891
General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.
Issues related to tax reform. Issues related to R&D tax credit.
H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions.
Literal federal measure citations: H.R.1968, H.Con.Res.14
Issues related to supply chain and tariffs.
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
